Global Amyotrophic Lateral Sclerosis Treatment Market

Amyotrophic Lateral Sclerosis Treatment Market Size, Share, Growth Analysis, By Treatment(Meditation, Stem Cell Therapy, Others.), By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Others (online pharmacies, diagnostics laboratories), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35J2089 | Region: Global | Published Date: July, 2036
Pages: 242 | Tables: 65 | Figures: 75

Amyotrophic Lateral Sclerosis Treatment Market Competitive Landscape

Global amyotrophic lateral sclerosis treatment market is slightly fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known. Some companies are Mitsubishi Tanabe Pharma Corporation, Sun Pharmaceutical Industries Ltd., CORESTEM, Inc, BrainStorm Cell Limited, Amylyx Pharmaceuticals Inc., AB Science, Ionis Pharmaceuticals, Biohaven Pharmaceutical, Biogen, and F. Hoffmann-La Roche AG.

Top Players in Amyotrophic Lateral Sclerosis Treatment Market

  • Mitsubishi Tanabe Pharma Corporation
  • BrainStorm Therapeutics
  • Biogen Inc.
  • Sanofi S.A.
  • Genentech Inc.
  • Cytokinetics Inc.
  • Avanir Pharmaceuticals, Inc.
  • Novartis International AG
  • Ionis Pharmaceuticals, Inc.
  • Neuraltus Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Anavex Life Sciences Corp.
  • AB Science
  • Biohaven Pharmaceutical Holding Company Ltd.
  • Ono Pharmaceutical Co., Ltd.
  • Bausch Health Companies Inc.
  • GW Pharmaceuticals plc
  • Mitsubishi Chemical Corporation
  • Regeneron Pharmaceuticals Inc.
  • Biocytogen, LLC.

Amyotrophic Lateral Sclerosis Treatment Market

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Amyotrophic Lateral Sclerosis Treatment Market size was valued at USD 662.30 million in 2022 and is poised to grow from USD 704.02 million in 2023 to USD 1147.77 million by 2031, growing at a CAGR of 6.3% in the forecast period (2024-2031).

Global amyotrophic lateral sclerosis treatment market is slightly fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known. Some companies are Mitsubishi Tanabe Pharma Corporation, Sun Pharmaceutical Industries Ltd., CORESTEM, Inc, BrainStorm Cell Limited, Amylyx Pharmaceuticals Inc., AB Science, Ionis Pharmaceuticals, Biohaven Pharmaceutical, Biogen, and F. Hoffmann-La Roche AG. 'Mitsubishi Tanabe Pharma Corporation', 'BrainStorm Therapeutics', 'Biogen Inc.', 'Sanofi S.A.', 'Genentech Inc.', 'Cytokinetics Inc.', 'Avanir Pharmaceuticals, Inc.', 'Novartis International AG', 'Ionis Pharmaceuticals, Inc.', 'Neuraltus Pharmaceuticals, Inc.', 'Pfizer Inc.', 'Anavex Life Sciences Corp.', 'AB Science', 'Biohaven Pharmaceutical Holding Company Ltd.', 'Ono Pharmaceutical Co., Ltd.', 'Bausch Health Companies Inc.', 'GW Pharmaceuticals plc', 'Mitsubishi Chemical Corporation', 'Regeneron Pharmaceuticals Inc.', 'Biocytogen, LLC.'

Global amyotrophic lateral sclerosis treatment market is projected to be driven by a rise in prevalence of amyotrophic lateral sclerosis disease. According to the Centers for Diseases Control and Prevention (CDC), in 2016, between 14,500 and 15,000 people in the U.S. had amyotrophic lateral sclerosis, of these about 5,000 people are diagnosed annually. Globally, about 2 – 5 people in every 100,000 are affected by ALS. Additionally, inclination toward sedentary lifestyle and increase in the geriatric population fuel the demand for targeted and symptomatic treatment options. This is expected to drive the market during the forecast period.

Due to the hectic schedule of the individual and changing lifestyle there is rising incidences of neurodegenerative disorders which is driving the global amyotrophic lateral sclerosis treatment market. Beside this, expanding geriatric population, who are more susceptible to such neurological ailments, is also augmenting the market growth. Furthermore, several NGO and private organizations are undertaking numerous initiatives to increase awareness regarding the diagnosis and treatment of ALS among the masses. This, in turn, is creating a positive outlook for the market. Additionally, the growing penetration of targeted symptomatic treatment options for ALS is acting as a significant growth-inducing factor.

North America had the largest market share in 2018 and is expected to maintain that position throughout the forecast period. The factors driving the market are high healthcare expenditure, favorable reimbursement policies, high demand for ALS drugs, and established healthcare infrastructure. According to the Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report, approximately 16,583 cases of amyotrophic lateral sclerosis were identified in the United States in 2015.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Amyotrophic Lateral Sclerosis Treatment Market

Report ID: SQMIG35J2089

$5,300
BUY NOW GET FREE SAMPLE